Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
HMGCS2, LysoPC, and Pulmonary Fibrosis
2026-09-11
Yang et al. identify injured type II alveolar epithelial cells as a major source of lipid accumulation in experimental pulmonary fibrosis and connect reduced HMGCS2 activity with LysoPC-mediated fibroblast activation. Their multi-model study positions epithelial lipid catabolism, PPARα signaling, and CPT1A/CPT2 regulation as mechanistic links that may guide future fibrosis research.
-
Hypoxia-Primed MSCs Transfer Mitochondria via Gap Junctions
2026-09-10
Luo et al. show that hypoxia-preconditioned human bone marrow mesenchymal stem cells improve liver ischemia-reperfusion injury by combining mitochondrial quality control with enhanced gap-junction-mediated mitochondrial transfer. The study identifies Cx43 and Cx32 as functionally important junctional routes and uses pharmacological, biochemical, and genetic approaches to connect connexin activity with graft protection.
-
Bay 11-7085: NF-κB Activation Inhibitor Guide
2026-09-10
Bay 11-7085 is a practical chemical probe for separating NF-κB-dependent inflammation from cell-cycle arrest and apoptosis. This workflow connects TNFα challenge assays with ER-stress neuroinflammation, endometriosis, and pneumococcal meningitis research while emphasizing controls that prevent overinterpreting cytotoxicity as pathway inhibition.
-
JSH-23: Mechanistic Guide to NF-κB Inhibition
2026-09-09
JSH-23 is an NF-κB inhibitor designed to separate p65 nuclear transcription from upstream IκB degradation. This guide connects its mechanism to inflammation research, PRV biology, assay design, and translational disease models.
-
FH1 (Catalog No. B3700) for iHep Maturation
2026-09-09
Learn how FH1 (Catalog No. B3700; SKU B3700) can support more functional iPS cell-derived hepatocyte models through increased albumin secretion, higher CYP3A4 levels, and reduced AFP. This scenario-based guide covers assay interpretation, formulation, storage, workflow controls, and practical supplier selection.
-
Catalpol in Alzheimer’s Disease: Mechanisms and Evidence
2026-09-08
The 2022 review by Chen et al. synthesizes preclinical evidence that catalpol may influence Alzheimer’s disease through anti-inflammatory, antioxidant, antiapoptotic, mitochondrial, and neuroprotective mechanisms. Its main value is an integrated mechanistic framework, while its review design also requires caution when translating heterogeneous cellular and animal findings into clinical expectations.
-
FPH1 (BRD-6125) Hepatocyte Proliferation
2026-09-08
A practical, scenario-based guide to using FPH1 (BRD-6125), SKU B3701, in primary human hepatocyte culture and iPS-derived hepatocyte workflows. It explains assay design, solvent handling, functional readouts, interpretation, and vendor-selection considerations without overstating evidence.
-
3-Hydroxybutyrate (BHBA) Assay Design
2026-09-07
This scenario-based guide explains how 3-hydroxybutyrate (BHBA), SKU M1297, can improve the design and interpretation of metabolic, viability, ferroptosis, and epigenetic cell assays. It connects product specifications with recent ketone-body research while clearly separating BHBA-specific evidence from broader ketone-body findings.
-
7ACC2: A Flux-Centered Guide to Tumor Metabolism
2026-09-07
7ACC2 is a monocarboxylate transporter 1 inhibitor that enables compartment-aware analysis of lactate and pyruvate flux. This guide connects its transport pharmacology with the 25-hydroxycholesterol–AMPK–STAT6 biology of tumor-associated macrophages while emphasizing rigorous assay interpretation.
-
ML-7 hydrochloride: MLCK Workflow Guide
2026-09-05
ML-7 hydrochloride gives cardiovascular researchers a practical way to perturb the cardiac myosin light chain kinase pathway while tracking contractility, cell death, metabolism, and endothelial barrier behavior. This workflow guide connects MLCK-mediated phosphorylation of myosin light chain to time-resolved ischemia/reperfusion assays and troubleshooting decisions.
-
FH1: A Functional Maturity Framework for iHeps
2026-09-04
FH1 is a small molecule for evaluating functional maturation during iPS cell differentiation to hepatocytes. This article presents an assay-centered framework that connects albumin, CYP3A4, AFP, morphology, and emerging translational gene-control methods without confusing maturation with gene-expression control.
-
Ellagic acid for CK2 and Senescence Assays
2026-09-04
Ellagic acid provides a practical CK2 perturbation tool for cancer biology research, apoptosis research, and oxidative stress assay design. Its biochemical selectivity, DMSO handling requirements, and compatibility with paired senescent-versus-proliferating workflows make it useful for connecting target engagement with phenotype rather than relying on viability data alone.
-
Danazol Rat Models: From Signal to Phenotype
2026-09-03
Danazol research is most informative when steroid signaling is connected to whole-animal developmental phenotypes. This article explains how Danazol and Danocrine-based rat models reveal hypothalamic–pituitary–gonadal axis changes, how to select orthogonal assays, and where the 2025 herbal-extract evidence remains preclinical.
-
Rapamycin at the mTOR–Microbiome Interface
2026-09-03
Rapamycin (Sirolimus) is more than a potent mTOR inhibitor: it is a translational probe for connecting nutrient signaling, immune regulation, cell-state control, mitochondrial disease biology, and gut microbiome interactions. This article examines how to design stronger experiments around mechanism, exposure, phenotype, and pharmacobiomics while positioning Rapamycin as a strategic research tool rather than a one-dimensional pathway reagent.
-
NLRP3 S-Acylation Gates Golgi Access
2026-09-02
Williams and Peden show that S-acylation of NLRP3 at conserved Cys-130, together with nearby hydrophobic residues and a polybasic region, controls recruitment to the Golgi. Their findings support a model in which nigericin-induced Golgi dysfunction reduces de-acylation and immobilizes NLRP3, linking organelle stress to inflammasome receptor localization.